While we are approaching the end of another calendar year, there are still some memories of 2012. The biggest fear in 2012 was: the world is coming to an end on 21st December, 2012. Well, it is more than a year – and the world has yet not ended.
At the same time, one may wonder if the world has changed dramatically. Let us look at some of the events that took place in 2013. These events shook our long-held beliefs.
In the beginning of the year, the safest asset – gold, after having a decade long bull run, saw weakness. What happened in April was unbelievable for most – In a sudden move, gold prices (in Indian Rupees) were down more than 20 percent from their peak. Barring a surge in July-August due to the weakness of Indian Rupee against world currencies, Gold has been quite lackluster throughout the year. Before the year began, it was believed to be a safe haven.
The popular belief was that in times of crisis, one rushes to Gold. Well, the safe haven is roughly 17 percent down compared to last year’s price.
Top 5 Dividend Companies To Buy For 2016: United Insurance Holdings Corp (UIHC)
United Insurance Holdings Corp. (UIHC), incorporated on May 22, 2007, is a holding company for United Property and Casualty Insurance Company and its affiliated companies. Its business is conducted principally through four wholly-owned subsidiaries, including United Property and Casualty Insurance Company (UPC), which writes insurance policies; United Insurance Management, L.C. (UIM), the managing general agent that manages substantially all aspects of UPC's business, Skyway Claims Services, LLC (SCS), a claims adjusting company that provides services to UPC; and UPC Re. UPC Re provides reinsurance protection to UPC.
The Company offers standardized policies for a range of exposures, and its policies include coverage options for standard single-family homeowners, tenants (renters), and condominium unit owners. It also writes flood policies. The Company has authorization to write a commercial line of business in Florida that includes auto and multi-peril coverage but the Company does not write commercial business. The Company offers standardized policies for a broad range of exposures, and its policies include coverage options for standard single-family homeowners, tenants (renters), and condominium unit owners.
The Company competes with Citizens Property Insurance Corporation, State Farm Florida Insurance Company, Universal Property & Casualty Insurance Company, St. Johns Insurance Company, Inc., United Services Automobile Association, American Coastal Insurance Company, Florida Peninsula Insurance Company, Security First Insurance Company, Homeowners Choice Property & Casualty Insurance Company, Inc., United Property & Casualty Insurance Company, Tower Hill Prime Insurance Company, Federal Insurance Company, USAA Casualty Insurance Company, Castle Key Insurance Company, American Integrity Insurance Company of Florida, Tower Hill Signature Insurance Company, ASI Assurance Corp., Tower Hill Preferred Insurance Company, Chartis Property Casualty Company and Universal Insurance C! ompany of North America.
Advisors' Opinion:- [By , Zacks Investment Research]
United Insurance Holdings Corp (UIHC) is a holding company that focuses primarily on providing homeowners’ insurance in Florida, South Carolina, Massachusetts, Rhode Island and North Carolina. It is headquartered in St. Petersburg, Fla., and has a market cap of $348 million.
- [By Louis Navellier]
United Insurance Holdings (UIHC) is a great example of a best of the best stock that should climb the wall of worry this summer. Writing homeowners and flood insurance might not be the most exciting business sin the word but the fundamentals of this company are really exciting.
5 Best Safest Stocks To Own Right Now: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Monica Gerson]
Merrimack Pharmaceuticals (NASDAQ: MACK) dipped 15.38% to $2.86 after the company reported that Phase 2 study Of MM-121 missed primary endpoint.
IAC/InterActiveCorp (NASDAQ: IACI) shares fell 14.51% to $49.50 in the pre-market trading after the company reported downbeat Q3 revenue.
- [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
5 Best Safest Stocks To Own Right Now: MedAssets Inc.(MDAS)
MedAssets, Inc. provides technology enabled products and services for hospitals, health systems, and other non-acute healthcare providers in the United States. It operates in two segments, Spend and Clinical Resource Management, and Revenue Cycle Management. The Spend and Clinical Resource Management offers a suite of cost management services, supply chain analytics, and data capabilities; medical device and clinical resource consulting, which includes implantable physician preference items, utilization management, and service line consulting; supply chain outsourcing and procurement services; capital equipment lifecycle management; lean process and workforce optimization solutions; process improvement consulting; business intelligence tools; and performance analytics and data management tools, such as service line analytics, spend analytics and strategic information services, e-commerce, client master item file services, electronic contract portfolio catalog, and decision support services. The Revenue Cycle Management segment provides a suite of products and services spanning the revenue cycle workflow from patient access and financial responsibility; case management, coding, and documentation; charge capture and revenue integrity; strategic pricing; claims processing; denials management and reimbursement integrity; revenue cycle and supply chain integration; revenue recovery and accounts receivable management; and outsourced services. It delivers technology-enabled solutions primarily through the company-hosted software, software-as-a-service, or Web-based applications. As of December 31, 2011, the company served approximately 4,200 acute care hospitals and 100,000 ancillary or non-acute provider locations. MedAssets, Inc. was incorporated in 1999 and is headquartered in Alpharetta, Georgia.
Advisors' Opinion:- [By Javier Hasse, Insider Monkey]
Fundamentally, ADT looks appealing. Its stock trades at 16.5 times the company�� earnings, versus an industry average of 29.4x, while it boasts industry leading margins and above average returns on equity and assets. However, above-average debt levels are concerning, so its financial standing must be further analyzed.
MedAssets (MDAS)The second company in this list is MedAssets (MDAS), a $1.37 billion market cap provider of technology-enabled products and services.
5 Best Safest Stocks To Own Right Now: Chalmers Ltd (CHR)
Chalmers Limited is an Australia-based company engaged in transport, logistic services, warehousing and container storage, repairs and sales. The Company operated in three segments: Transport, Containers and Property. Transport consists of road transport, predominantly import/export FCL containers and the interface with logistics/ warehousing/hubbing services. Containers represent the empty container park operations concerned with handling, storage, repairs, upgrades, pretrips and so on of empty containers on behalf of shipping and leasing company customers. Property represents the capital investment Chalmers has in freeholds located in Melbourne. The Company�� subsidiaries include Chalmers Industries Pty Ltd, Chalmers (Australia) Pty Ltd and Chalmers Industries (Brisbane) Pty Ltd. Advisors' Opinion:- [By Corinne Gretler]
Chr. Hansen A/S (CHR) slid 1.7 percent to 186 kroner after Credit Suisse Group AG cut the stock to neutral, the equivalent of hold, from outperform. The brokerage said that profit from its natural-color business remains under pressure. The world�� biggest maker of dairy enzymes cut its full-year sales forecast on July 3 because of lower prices for the red pigment carmine.
No comments:
Post a Comment